Research

Communication and Advancement Awards Report Fiscal Year 2001
Medical Center Area
Medicine
Internal Medicine

Primary Total: $8,685,929.
 Collaborative Total: $11,386,759.

ALAN DAUGHERTY
Scavenger Receptor Modulation of Atherogenesis, (461522), Natl Heart Lung and Blood Institute, $334,989.00

ALAN DAUGHERTY
Atherogenic Effects of Interferon-gamma, (464440), American Heart Assoc, $71,500.00

ALAN DAUGHERTY
Effects of ZD 4522, (464628), AstraZeneca, $108,332.00

ALAN DAUGHERTY/LISA CASSIS/JIM PAULY
AngII Promotes Proinflammatory processes in Atherogenesis, (464240), Natl Heart Lung and Blood Institute, $351,250.00

ALAN DAUGHERTY/STEWART WHITMAN
Absence of Interferon-Gamma Increases Atherogenesis, (463032), American Heart Assoc Ohio Valley Affiliate, $30,000.00

ALFRED COHEN/CHANGQING XUN
* Non-Chytotoxic Conditioning for Allogeneic Stem Cell Transplant, (464512), Natl Marrow Donor Program, $35,000.00

ANDREA NATALE
Right Ventricular Outflow Versus Apical Pacing in Pacemaker Patients with Congestive Heart Failure and Atrial Fibrillation (ROVA Trial), (462243), Pacesetter Inc, $848.00

ANDREA NATALE
METRIX - Automatic Atrial Defibrillation System, (461436), InControl, $200.00

ANDREA NATALE
Evaluation of Efficacy of the Cordis Webster NAVI-STAR and REF-STAR and REF-STAR Catheters used in conjuction with the CARTO Mapping System and a Radionics Radiofrequency Generator, Medtronic CardioRhythm Atakr radiofrequency, (461492), Cordis Webster Inc, $252.00

ANDREA NATALE
Feasibility Evaluation of Radiofrequency Ablation of Typical (Type 1) Atrial Flutter Using the Navistar DS (8mm Tip) Catheter With the Stockert EP Shuttle Generator, (462885), Cordis Webster Inc, ($2.00)

BARBARA PHILLIPS
Sleep Academic Award, (461364), Natl Heart Lung and Blood Institute, $86,694.00

BETH GARVY
Host Defense Against P. Carinii in Neonatal Mice, (462489), Natl Heart Lung and Blood Institute, $220,500.00

BETH GARVY
Host Defense Against PCarinii in Neonatal Mice, (463374), Natl Heart Lung and Blood Institute, $237,143.00

BETH MILLER
A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol 42 mcg (2 Puffs) Twice Daily, (464471), Glaxo Wellcome, $2.00

CHANDRACHURANAN GAIROLA/ALAN DAUGHERTY
* Toxicological Comparison of Smokes from Standard and Patented, Additive-Modified Tobacco Cigarettes in Mouse Models, (464097), Rousseau Research Inc, $351,000.00

CHANGQING XUN/STEPHEN BROWN/BETH GARVY/JOHN THOMPSON/DAOHONG ZHOU
Non-Myeloablative Histoincompatible Stem Cell Transplant, (464232), Natl Cancer Institute, $129,542.00

CHIEN KUO
Mode Selection Trial in Sinus Node Dysfunction - MOST, (461516), Mount Sinai, $2,700.00

CHIEN KUO/FABIO LEONELLI
Atrial Fibrillation Follow-up Investigation of Rhythm Management, (460500), Statistics and Epidemiology Research Co, $1,180.00

CHIEN KUO/FABIO LEONELLI
Biventricular Pacing in Congestive Heart Failure (VIGOR), (462567), Guidant/CPI, $1,000.00

CHIEN KUO/JOHN GURLEY
Atrial Conversion Efficacy with Delay - Atrial Fibrillation (ACED-AF), (464799), Medtronics Inc, $2.00

CLAIRE POMEROY/RICHARD GREENBERG/ARDIS HOVEN/PATRICIA JENNINGS/IGHOVWERHA OFOTOKUN/FRANK ROMANELLI/ALICE THORNTON
KY Aids Educational Training Center, (464810), Wayne State Univ, $10,000.00

CLAIRE POMEROY/ROBERT BLOUIN/RICHARD KRYSCIO
Career Training in Therapeutics & Translational Research, (464451), Natl Heart Lung and Blood Institute, $200,000.00

CRAIG JORDAN
Molecular Characterization of Human Hematopoietic Stem Cells, (462480), Princeton Univ, $33,117.00

CRAIG JORDAN
Preliminary Application: The Generation of Leukemia Vaccines, (462156), Leukemia Society of America Inc, $107,434.00

CRAIG JORDAN
Novel Therapeutics for the Treatment of Hematologic Cancers, (464620), Deltagen Inc, $173,812.00

CRAIG JORDAN
A Novel Antibody-based Immunotherapy Treatment for AML, (464472), Natl Leukemia Research Assoc Inc, $20,000.00

CRAIG MCCLAIN
TNF and Mitochondrial Dysfunction in ALD, (429711), Natl Institute on Alcohol Abuse and Alcoholism, ($310,146.00)

DANIELL HILL
Prostaglandin Therapy for Alcoholic Hepatitis, (463630), Natl Institute on Alcohol Abuse and Alcoholism, $111,022.00

DAOHONG ZHOU
Radiation-Induced Lymphoid and Hematopoietic Toxicity, (464188), Natl Cancer Institute, $7,755.00

DAOHONG ZHOU
Stressor-Induced Modulation of Inducible NO Production, (460806), Natl Institute of Mental Health, ($59,443.00)

DAOHONG ZHOU/STEPHEN BROWN/CHESTER JENNINGS/JOHN THOMPSON
Prophylaxis of aGVHD by Inhibiting IR induced NFkB Activation, (463756), Natl Cancer Institute, ($150,509.00)

DAVID BOOTH
A Randomized, Double Blind, Placebo Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor, Adenosine Injection) as an Adjunct to Reperfusion Therapy (Thrombolysis or Mechanical Reperfusion in the ..., (463078), Quintiles Inc, $2,518.00

DAVID RUDY/CHARLES GRIFFITH/J WILSON
Interactive Workshops in Communication and Interviewing Skills with Elderly Patients for Internal Medicine Residents, (464499), JVC Radiology and Medical Analysis LLC, $20,000.00

DAYONG GAO/GARY VAN ZANT
* Selection and Storage of Hematopoietic Stem Cells in a Novel Bioreaction, (463482), Cytomatrix, $41,580.00

DEBORAH KWOLEK/STEVEN HAIST
Multidisciplinary Instrucitonal modules for Women's Health Education, (464356), Fund for the Improvement of Postsecondary Ed, $147,418.00

DENEYS VAN DER WESTHUYZEN
Class B Scavenger Receptors and Foam Cell Formation, (464222), Natl Heart Lung and Blood Institute, $220,500.00

DENEYS VAN DER WESTHUYZEN/FREDERICK DEBEER
SR-BI Influence of apoAII, (464145), Natl Heart Lung and Blood Institute, $252,000.00

DENNIS DOHERTY
Intracellular Pathways Regulating Monocyte Survival, (464284), Ohio State Univ, $19,645.00

DENNIS DOHERTY
A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics, (463623), Merck and Company Inc, $14,192.00

DENNIS DOHERTY
A Double-Blinded, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of L-753099 in Patients with COPD (Protocol 013-00), (463678), Merck and Company Inc, $12,202.00

DENNIS DOHERTY
A One-Year Randomized, Double-Blind, Placebo and Active-Controlled Parallel Design SAfety and Effiacy Comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in Patients with COPD, (464330), Boehringer Ingelheim, $32,213.00

DENNIS DOHERTY
Validation of Outcome Measures for Chronic Obstructive Pulmonary Disease for Use in Phase III M3(L-753,099) Program, (463911), Merck and Company Inc, $10,431.00

DENNIS DOHERTY
A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter, Pareallel-Group, Dose Ranging Study of L-753099 in patients with COPD, (463919), Merck and Company Inc, $13,396.00

DENNIS DOHERTY
A Randomized Open-Label, Pilot Assessment of the Effect of Protonix I.V. for Injection (Pantoprazole Sodium) on Gastric pH in ICU Patients. Protocol #3001K1-912-US, (463990), Wyeth Ayerst, $17,608.00

DENNIS DOHERTY
A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg DISKUS inhaler bid versus Fluticasone Propoinate 250 mcg DISKUS inhaler, (464010), Glaxo Wellcome, $2,498.00

DENNIS DOHERTY
* Scope for Study #303 A Randomized, DoubleBlind, Multicenter Study Comparing the Efficacy and Safety of Piperacillin/ Tazobactam (4 G/500 MG) to Imipenim/Cilastatin (500MG/500MG) Administered Intravenously Every Six Hours, (471385), Wyeth Ayerst Research Inc, $1,000.00

DENNIS DOHERTY
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcantaneous Recombinant Interferon Gamma-1b (1FN-y 1b) in Patients with Idiopathic Pumonary Fibrosis" GIPF-001, (464742), InterMune Pharmaceuticals, $2.00

DENNIS DOHERTY
A Multicenter, Randomized, Placebo and Active-Controlled, Five-Way, Crossover Study of (R,R), Formoterol Tartrate Inhalation Solution and Salmeterol in Subjects with Chronic Obstructive Pulmonary Disease, (464522), SEPRACOR Inc, $6,741.00

DIANNA HOWARD
00-BMT-126: A Phase III Clinical Trial of Immunotherapy with Humanized LL2 IgG (Epratuzumab) in Patients with Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) (IM-T-hLL2-07), (464495), AMGen, $2.00

DONNA REECE
01-BMT-128: Phase 2 Study of Genasense (Bcl-2 Antisense) Combined with Mylotarg(Gemtuzumab Ozogamicin) in Elderly Patients with Relapsed Acute Myeloid Leukemia, (464745), Genta Inc, $2.00

DONNA REECE
01-BMT-127: Randomized Phase 3 Study of Dexamtehasone with or without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients with Relpased or Refractory Multiple Myeloma, (464746), Genta Inc, $2.00

DONNA REECE
00-BMT-120: Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-Cell Non-Hodgkin's Lymphoma at Second or Later Relapse, (463755), INEX Pharmaceuticals Co, $5,348.00

DONNA REECE
99-BMT-103: Orally for Compassionate Use in Patients with Significant Resistant Bacterial Infections, (463024), Pharmacia & Upjohn Inc/Millard Fillmore Hlth Syst, $250.00

DONNA REECE
97-BMT-86 Phase I/II Study of High Dose Cyclophosphamide, Thiotepa and Carboplatin (CTCb) and Autologous Hemato- poietic Stem Cell Transplantation (AHSCT) in Conjunction with Immunomodulation with an Anti Idiotype Vaccine..., (463053), AMGen, $18,000.00

DONNA REECE/DIANNA HOWARD/CLAIRE POMEROY/JOHN THOMPSON
Allo Stem Cell Transplant for High Risk Hematologic Cancer Patients from Closely Matched Related Donors, (464666), Univ of Maryland at Baltimore, $67,464.00

EDWARD ROMOND
* NSABP Master Agreement, (461778), NSABP Fdtn, $59,560.00

EMERY WILSON/CLAIRE POMEROY/PHYLLIS WISE
* Interdiscplinary Research Careers in Women's Health, (464297), Natl Institute of Child Health and Human Develop, $500,000.00

EMERY WILSON/CRAIG MCCLAIN
* General Clinical Research Center, (463469), Natl Center for Research Resources, $62,781.00

ERIC SMART/ALAN DAUGHERTY/DENEYS VAN DER WESTHUYZEN
* SR-BI and Macrophage Cholesterol Metabolism, (463557), Natl Heart Lung and Blood Institute, $304,768.00

FABIO LEONELLI
Low Energy Safety Study (LESS), (463346), Guidant/CPI, ($2.00)

FABIO LEONELLI/CHIEN KUO/TIBOR SZABO
DDD versus DDDR Pacing: A Quality of Life Study, (460124), Pacesetter Inc, $300.00

FREDERICK DEBEER
sPLA2:, (461160), Natl Institute on Aging, $120,202.00

FREDERICK DEBEER/NANCY WEBB
SR-BI Mediated Selective Cholesterol Ester Uptake, (464539), Natl Institute on Aging, $220,500.00

FREDERICK SCHMITT/NANCY STILES
* Eisai Donepezil Hydrochloride in Ad Study, (464647), Quintiles Inc, $2.00

GARY VAN ZANT
Cytokine Based Purging of Stem Cells Using a Novel Bioreactor, (463387), Cytomatrix, $74,826.00

GARY VAN ZANT
Mouse Models for the Study of Longevity Genes, (462707), Natl Institute on Aging, $617,181.00

GARY VARILEK
Safety, Tolerance and Efficacy of Treatment with Subcutaneous rHuIL-10 (SCH 52000) in Subjects with Steroid Dependent Crohn's Disease, (462151), Schering Plough Co, $4,562.00

GARY VARILEK
Green Tea and Inflammatory Bowl Diseasse, (464127), Natl Institute Diabetes & Digestive & Kidney, $72,500.00

GARY VARILEK
Cytokine Modulation of Inflammatory Bowel Disease, (460373), Natl Institute Diabetes & Digestive & Kidney, $40,706.00

GARY VARILEK
A Six Month, Randomized, Double-Maked, Placebo-Controlled, Three Arm Study to Evaluate the Safety and Efficacy of ISIS 2302 in Steriod-Dependent Crohn's Disease, (461403), Isis Pharmaceuticals Inc, $2,900.00

GARY VARILEK
A Comparative Efficacy Study of Esomeprazole Magnesium (40mg qd) and Lansoprazole (30 mg qd) in Patients with Erosive Esophagitis, (464295), AstraZeneca, $2.00

HANNA MAWAD/ROBERT FRIEDLER/HARTMUT MALLUCHE
An open label, randomizing, multicenter, phase III, comparator controlled parallel group study to assess the long term safety and efficacy of Lanthanum Carbonate in CRF patients recieving hemodialysis., (464409), Shire Laboratories Inc, $27,717.00

ION DEACIUC/EUN LEE
Apoptosis in Alcoholic Liver Disease, (463646), Natl Institute on Alcohol Abuse and Alcoholism, $217,300.00

JAMES ANDERSON
An Open-Label, Multinational, Multicentre, Extension Trial to Assess the Long-Term Safety and Efficacy of ZD4522 in Subjects in the ZD4522 Clinical Trial Program, (463726), AstraZeneca, $2,683.00

JAMES ANDERSON
A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Study to Investigate the Efficacy and Tolerability of 300 mg/day and 400 mg/day of Bupropion SR Compared to Placebo for the..., (463727), Obesity Research Network, $106,685.00

JAMES ANDERSON
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Investigate the Tolerability and Efficacy of Oral 1555U88 (2.5mg, 5mg, 10mg, or 15mg per day) Compared to Placebo for the Treatment of Obesity in Subjects 18-65 Years of Age., (463578), Glaxo Wellcome, $44,706.00

JAMES ANDERSON
A Phase III Multi-Center, Two Arm Study to Assess the Efficacy and Safety of Ecopipam (SCH 39166) in the Management of Obesity, (463597), Schering Plough Co, $145,363.00

JAMES ANDERSON
A Randomized, Double-Blind, Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburind/Glibenclamide in Patients with Drug-Naive, (463603), Smith Kline Beecham, $7,003.00

JAMES ANDERSON
A Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Trial of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (A0-128) in Type II Diabetes Mellitus Patients (non-insulin dependent diabetes mellitus, NIDDM), (460229), Quintiles Inc, $506.00

JAMES ANDERSON/ROBERT FREDERICH JR
A Comparison of the Long Term Efficacy of Self Help Weight Loss Versus a Commercial Weight Loss Program, (461671), Weight Watchers International, $25,069.00

JAMES ANDERSON/ROBERT FREDERICH JR
A 1-Year Follow-up Evaluation of Patients Who Participated in the Wyeth-Ayerst Research Study 0927A1-915-US, (462670), Covance, $1,300.00

JAMES ANDERSON/ROBERT FREDERICH JR
Safety and Efficacy of Fixed Combination Metformin/ Glyburide Products as First Line Therapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Control With Diet and Exercise, (461893), Bristol Myers Squibb Company, $1,088.00

JAMES ANDERSON/ROBERT FREDERICH JR
A Multicetner, Double-Blind, Randomized, Placebo-controlled, Parallel Group, 18 Month Study to Assess the Safety and Efficacy of Meridia (Sibutramine Hydrocholoride) 20 mg When Given in Titrated Doses to Patients with Obesity, (462215), Knoll Pharmaceutical Company, $13,449.00

JAMES ANDERSON/ROBERT FREDERICH JR
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Parallel Group Study to Examine the Long-Term Efficacy and Safety of Meridia (sibutramine hydrochloride) in Obese Patients, (462236), Knoll Pharmaceutical Company, $70,169.00

JAMES ANDERSON/ROBERT FREDERICH JR
A 52-Week, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Orlistat Treatment in Obese Patients With Type 2 Diabetes Inadequately Controlled With Insulin, (462395), Roche Laboratories, $15,217.00

JAMES ANDERSON/ROBERT FREDERICH JR
A 52-Week, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Orlistat Treatment Plus Diet in Obese Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy, (462396), Roche Laboratories, $11,110.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
Evaluation of the Safety and Efficacy of Nicostatin (A Combination Tablet of Niacin Extended-Release/Lovastatin Immediate-Release) A Dose Ranging Study, (462742), Kos Pharmaceuticals, $16,950.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
A Multi-Center, Randomized, Parallel-Group, Open-Label, Glyburide-Controlled Cardiac Safety Study of Oral GI262570 Sodium Tablets (7.5mg) or Micronized Glyburide 6-12mg Administered for 24 Months to Subjects with Type 2 Diabetes, (463418), Glaxo Wellcome, $8,167.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
A Multicenter, Radomized, Double-Blinded, Parallel-Group, Placebo-Controlled Evaluation of Oral GI262570 Sodium Tablets (2.5 mg, 5 mg, and 7.5 mg) in Combination With Current Insulin Therapy for 26 Weeks Duration in Subjects..., (463386), Glaxo Wellcome, $3,020.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
Evaluation of the Safety and Efficacy of Nicostatin (a Combination Extended Release/Lovastatin Immediate Release) an Open-Label Extension Study, (463280), Kos Pharmaceuticals, $2,500.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
A 24 Week Randomized Double Blind Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 & Atorvastatin in the Treatment of Subjects With Hypercholesterolaimia and Documented Athersclerosis, (463175), AstraZeneca, $14,706.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
A Double-Blind, Placebo-Controlled, 54-week Study of the Efficacy and Safety of Xenical (Orlistat) in the Weight Management of Obese Pediatric Patients, (464496), Hoffmann La Roche Inc, $6,240.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
A Randomized, Parallel, Open Label, Muti-Center Study to Evaluate and Characterize Weight Loss Associated with 12 Weeks use of a Nutrional Beverage Containing Ethyl Oleate as a Meal Replacement., (464619), Proctor & Gamble Company, $64,377.00

JAMES ANDERSON/ROBERT FREDERICH JR/L REYNOLDS
A Randomized, double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Safety of Topiramate in the Treatment of Subjects with Obesity., (464209), R W Johnson Pharmaceutical Research Institute, $82,019.00

JAMES BRYSON
Anti-Tumor Potential of Autologous/Syngeneic GVHD, (461940), Natl Cancer Institute, $224,200.00

JAMSHED KANGA/MICHAEL ANSTEAD
* Cystic Fibrosis Center Program, (464157), Cystic Fibrosis Fdtn, $67,493.00

JAY MASON
SCOR in Sudden Cardiac Death, (463551), Univ of Utah, $91,406.00

JAY MASON
SCOR in Sudden Cardiac Death, (464488), Univ of Utah, $157,798.00

JOHN GURLEY
Prevention of Sudden Cardiac Death Heart Failure Trial (SCD-HEFT), (461793), Duke Univ Medical Center, $150.00

JOHN GURLEY/JEFFREY CLEVENGER
A Double-Blind, Placebo-Controlled, Multinational Trial to Investigate the Effect of the Na+/H+ Exchange Inhibitor HOE642 on All-Cause Mortality & MI in Patients at Risk of Myocardial Necrosis due to Acute Coronary Syndrome R/T th, (460808), Hoechst Roussel, $554.00

JOHN THOMPSON
* Therapy Groups to Study T Cell Depletion Trial, (433616), Natl Heart Lung and Blood Institute, $3,600.00

JOHN THOMPSON/BRUCE LUCAS
Controlled, Randomized, Open-Label, Multicenter de NOVO Study Cmparing SANG-35 Oral Solution with Neoral Capusules in Adult Renal Allograft Recepients, (462468), Southeastern Organ Procurement Foundation, $3,400.00

JOHN THOMPSON/BRUCE LUCAS
* A Three-Year, Randomized, Multicenter, Double-blind, Double- Dummy, Parallel Group Study of the Efficacy and Safety of SD Z RAD Tablets vs Mycophenolate Mofetil as Part of Triple Immunosuppressive Therapy in DeNovo Renal Transplant Recipie, (462629), Novartis, ($14,299.00)

JOHN WILLIAMS
Potential mechanisms of age-dependent bone loss, (464405), Natl Institute on Aging, $296,175.00

JOHN YANNELLI/EDWARD HIRSCHOWITZ
* CTL Defined Antigens in Non Small Cell Lung Cancer, (463151), Natl Cancer Institute, $271,932.00

KENNETH AIN
De-Methylation Therapy of Thyroid Carcinoma, (463751), Natl Cancer Institute, $52,672.00

KENNETH AIN
Preclinical Evaluation of Combretastatin A-4 in Anaplastic Thyroid Carcinoma, (464399), Oxigene Inc, $56,448.00

L REYNOLDS
The Efficacy of Rosiglitazone and Lifestyle Intervention Measures to Modify the Course of Insulin-Treated Obese Type 2 Diabetes Mellitus, (463514), Smith Kline Beecham, $36,953.00

L REYNOLDS
Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia i Insulin Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin, (463490), Hoechst Marion Roussel Inc, $9,000.00

L REYNOLDS/JAMES ANDERSON/ROBERT FREDERICH JR
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Evaluation of GI262570 Sodium Tablets (2.5mg, 5mg, 7.5mg) as a monotherappy for 26 Weeks in Subjects with Type 2 Diabetes Mellitus, (463419), Glaxo Wellcome, $13,440.00

LAURIE HAAS
A Twelve Week Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Alosetron Hydrochloride 1 mg Twice Daily for Control of Bowel Urgency in Females with Diarrhea-Predominant Irritable Bowel Syndr., (463328), Glaxo Wellcome, $80.00

LAURIE HAAS/NICHOLAS NICKL/HERBERT STEGER JR
Predictors of Patient Satisfaction and Tolerance of Gastrointestinal Endoscopy, (463825), American College of Gastroenterology, $10,000.00

LUIS MARSANO/STEVEN SHEDLOFSKY
Daily Interferon and Ribavirin for Patients with Chronic Hepatitis C and Normal Transaminases, (463700), Schering Plough Co, $15,998.00

LUIS MARSANO/STEVEN SHEDLOFSKY
A Phase III, Randomized, Multicenter, Efficacy and Safety Study Examining the Effects of the Duration of Treatment and the Daily Dose of Ribavirin in Patients with Chronic Hepatitis C Virus Infection Treated with the Combination..., (463420), Hoffmann La Roche Inc, $37,110.00

LUIS MARSANO/STEVEN SHEDLOFSKY
A Phase III Randomized, Multicenter, Efficacy and Safety Study Comparing the Combination of Pegylated-Interferon Alpha-2 and Ribavirin to Rebetron in the Treatment of Patients with Chronic HCV Infection, (462674), Hoffmann La Roche Inc, $43,219.00

LUIS MARSANO/STEVEN SHEDLOFSKY
Treatment of Chronic Hepatitis C Previously Not Responsive to Interferon with/without Ribavirin with PEG-Intron and Rebetol, (464156), Schering Plough Co, $4,998.00

LUIS MARSANO/STEVEN SHEDLOFSKY/MARCELLO KUGELMAS
Efficacy of INFERGEN for Chronic Hepatitis C in Patients for are Non Responders and Relapsers to Combination Therapy with Intron A + Ribavirin., (462996), AMGen, $2,640.00

MALCOLM AVISON/JOSEPH BERGER/RICHARD GREENBERG/RICHARD KRYSCIO/AVINDRA NATH/FREDERICK SCHMITT
* MRI Probes of BBB Integrity in HIV Dementia, (464314), Natl Institute of Mental Health, $253,750.00

MARCELLO KUGELMAS
An Open-Lable Trial in Hepatitis C Patients Who Receive an Initial Course of Therapy with Infergen 9mcg (12 weeks) and Retreatment With Infergen 15mcg (24 weeks) for Nonresponders, (462292), AMGen, $1,600.00

MARCELLO KUGELMAS
A Phase I Evaluation of the Saftey and Tolerability of Chrion Hepatitis B Infection Receiving Lamivudine, (462471), Chiron Corporation, $9,374.00

MARTIN EVANS
Tuberculosis Control Program, (464215), KY Department for Public Health, $15,000.00

MARTIN EVANS
Selection of Fluroguinoline Resistance in Methicillin Resistant S. Aureus: Comparison of Levofloxocin and Ciprofloxocin in an In-Vitro Model, (464691), Ortho McNeil Pharmaceuticals, $49,819.00

MICHAEL ANDRYKOWSKI/RITA MUNN/FREDERICK SCHMITT
* Cognitive Behavioral Aspects of Cancer-Related Fatigue, (463827), Univ of South Florida, $94,835.00

MICHAEL ANSTEAD/DENNIS DOHERTY
* Antiinflammatory Effect of Azithromycin in Cystic Fibrosis, (463224), American Lung Assoc, $1,451.00

MICHAEL DOUKAS
* Randomized, Double-Blind, Placebo-controlled, Phase III Study of the Matrix Metalloproteinase Inhibitor AG3340 in Combination with Mitoxantrone and Prednisone in patients having Metastatic Hormone-Refractory Prostate Cancer, (461939), Agouron Pharmaceuticals, $29,600.00

MOISES LANGUB JR/HARTMUT MALLUCHE
Regulation of Bone Turnover in Renal Osteodystrophy, (464558), Natl Institute Diabetes & Digestive & Kidney, $81,000.00

NANCY WEBB
Scavenger Receptor B-I: Distinct Functional Domains, (464441), American Heart Assoc, $65,000.00

NAUSHERWAN BURKI
Randomized, Double-Blind, Phase III, Comparative Study of Cidecina (Daptomycin) to Rocephina (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia due to S. Pneumoniae, (464478), Cubist Pharmaceuticals Inc, $5,400.00

NAUSHERWAN BURKI
Randomized, Multicenter, Phase III Study of Intravenous Treatment with Synercid Plus Aztreonam vs Standard Treatment in Nosocomial Pneumonia, (463028), Aventis Pharmaceuticals Products Inc, $32,800.00

NAUSHERWAN BURKI
Prospective, Multicenter, Doubleblind, Randomized Comparative Study to Evaluate the Efficacy Safety and Tolerability of MK-0826 vs Cefepime in the Treatment of Hospital-Acquired Pneumonia in Adults, (462840), Merck and Company Inc, $12,120.00

NICHOLAS KOSZEWSKI
Negative Regulation of Gene Expression by Vitamin D, (463116), Natl Institute Diabetes & Digestive & Kidney, $155,507.00

NICHOLAS NICKL
Prevention of Sporadic Colorectal Adenomas with Celecoxib, (464565), G D Searle & Co, $2.00

NICHOLAS NICKL
Hypoechoic Intramural Tumor Study, (464656), American Digestive Health Fdtn, $25,000.00

PAOLO FANTI
Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE), (464418), Bristol Myers Squibb Company, $2,050.00

PAOLO FANTI
Losartan Intervention for Endpoint Reduction in Hypertension, (429819), Merck and Company Inc, $7,626.00

PAOLO FANTI
Antioxidant and Antiinflammatory Effects of Dietary Isoflavones in ESRD, (463202), Protein Technologies International, $2,920.00

PAOLO FANTI/BRIAN JACKSON
Soyfoods and Prevention of Renal Disease in an Animal Model of Type I Diabetes Mellitus, Role of Renal Hemodynamics and Renal Microvascular Production of Nitric Oxide, (464384), Kidney Fdtn of Central KY, $18,897.00

PAOLO FANTI/DAVID RUDY
NESP Protocol 990788 --A Study Evaluating the Initiation & Titration of Fixed Doses of Novel Eythropoiesis Stimulating Protein (NESP) Therapy in Subjects with Chronic Renal Insufficiency (CRI), (464481), AMGen, $2.00

PAOLO FANTI/JAMES ANDERSON
Soy Protein Use in Early Diabetic Nephropathy, (463592), Natl Institute Diabetes & Digestive & Kidney, $144,430.00

PATRICIA JENNINGS/RICHARD GREENBERG/CLAIRE POMEROY/HERBERT RIDINGS/PAUL THORNTON
* Expanded HIV/AIDS Training Grant for Physician Assistants, (464029), Health Professions Bureau, $266,695.00

PEDRO MORENO
Detection by Near-Infrared Spectroscopy of Plaque Stabilization, (463658), InfraReDx, $24,784.00

PHILIP DESIMONE
* 98-LUN-37BP Randomized, Double-blind, Multi-Center, Placebo Controlled Study Comparing Single Agent, (462346), Bayer Pharmaceuticals, $3,375.00

PHILIP DESIMONE/JUSTINE YONEDA
* Phase II Randomized Study of Taxol, Paraplatin and Radiation Therapy for Locally Advanced Inoperable Non-small Cell Lung Cancer, (462293), American College of Radiology, $3,100.00

PHILIP DESIMONE/KENNETH FOON
* 96-GI-41SW: A Phase II, Randomized, Multicenter Comparison of the Efficacy of Oxaliplatin in Four Schedules of 5- Fluorouracil with and without Leucovorin in Previously Untreated Advanced Colorectal Cancer, (461030), Sanofi Winthrop Inc, $40,000.00

RAJENDER CHAWLA/CRAIG MCCLAIN
Alcoholic Liver Disease and S-Adenosylmethionine, (429707), Natl Institute on Alcohol Abuse and Alcoholism, ($21,750.00)

RALPH MILLER
The Hypopituituary Control and Complications Study, (461159), Eli Lilly and Company, $20,946.00

RICHARD GREENBERG
A 24-Week Phase II Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (DMP 266+ Indinavir, DMP 266+ Zidovudine + Lamivudine, Indinavir + Xidovudine + Lamivudine, (460913), DuPont Merck Pharmaceutical Company, $24,950.00

RICHARD GREENBERG
* 96-SC-05SP(SEQU-07-26/B): A Double-Blind, Randomized Study Comparing ABCD (Amphotericin B Colloidal Dispersion) and Fungizone in the Treatment of Febrile Neutropenic Patients Failing Broad Spectrum Antibacterial Therapy, (460740), Sequus Pharmaceuticals, $3,100.00

RICHARD GREENBERG
96-MISC-62PCR(150-602): An Open Randomized Comparative Multicenter Study of the Efficacy, Safety and Toleration of Voriconazole vs Amphotericin B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised, (461182), Pfizer Inc, $13,650.00

RICHARD GREENBERG
A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsule (sgc) TID Regiment in Combination with Two NRTIs Versus Saquinavir Soft Gel Capsule (sgc) BID Regimen in Combination with Two NRTIs, (461541), Roche Laboratories, $7,100.00

RICHARD GREENBERG
97-BMT-81: ABELCET (Amphotericin B Lipit Complex Injection) In the Fungal Prophylaxis of Patients Undergoing Donor or Mismatched Family-Related Donor Stem-Celll Tranplantation, (461733), Liposome Company, $2,141.00

RICHARD GREENBERG
96-SC-02 Open Label, Non Comparative, Multicenter, Phase III Trial of the Efficacy, Safeety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasi ve Fungal Infections, (461941), Covance, $24,164.00

RICHARD GREENBERG
97-BMT-84P: (Protocol #150-603 Study #97-N-0023) A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole vs Ambisome for Empirical Antifungal Therapy in immunocompromized patients with persistent Fever and Neutro, (461825), Pfizer Inc, $37,809.00

RICHARD GREENBERG
Protocol FTC-303: A Randomized, Open Label Study of FTC vs Lamivudine in Patients, on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine and a Protease Inhibitor, (462237), Triangle Pharmaceuticals, $3,388.00

RICHARD GREENBERG
A Multicenter, Randomized, Open-label, Trial of MERREM I.V. (meropenem, ICI 194,660) and PRIMAXIN I.V. (imipenem- cilastatin) for the Treatment of Community-acquired Bacterial Pneumonia, (462039), Zeneca, $52,283.00

RICHARD GREENBERG
An Open Non-Comparative Protocol of the Efficacy, Safety, and Toleration of Extended Voriconazole Treatment of Invasive Fungal Infections, (462705), Pfizer Inc, $20,567.00

RICHARD GREENBERG
LY333328 vs Vancomycin in Skin/Skin-Structure Infections, (462713), Eli Lilly and Company, $8,990.00

RICHARD GREENBERG
Phase II Clinical Trial to Evaluate the Safety and Effectiveness of an Enterocolonic Formulation of Bovine Anti-Clostridium difficile Toxin A and B Milk Immunoglobulin (DiffGAM) on Reducing the Severity of C. difficile, (462668), Immucell Corporation, $9,000.00

RICHARD GREENBERG
Phase II Clinical Trial to Evaluate the Safety and Effectiveness of an Enterocolonic Formulation of Bovine Anti-Clostridium difficile Toxin A and B Milk Immunoglobulin (DiffGAM) on Reducing the Severity of C. difficile, (462764), Advanced Biologics, $3,550.00

RICHARD GREENBERG
99-BMT-108: Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in High-Risk Group and an Observational Cohort Study in the Low Risk Group, (463645), Fujisawa Pharmaceuticals, $10,302.00

RICHARD GREENBERG
99-BMT-107: A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a hematopoietic Stem Cell Transplant., (463668), Fujisawa Pharmaceuticals, $43,739.00

RICHARD GREENBERG
00-BMT-117: (SCH56592-P00041) Open Lavel, Treatment Protocol for the Safety and Efficacy of SCH56592 in the Treatment of Invasive Fungal Infections., (463781), Schering Plough Co, $2,470.00

RICHARD GREENBERG
99-BMT-110: A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of MK-0991 versus (Amphotericin B) Liposome for Injection as Empiric Therapy in Patients with Persistent Fever and Neutropenia, (463750), Merck and Company Inc, $53,201.00

RICHARD GREENBERG
050: Safety, Tolerability of Two 2X40 mg Regimens of Recombivax, (463107), Merck and Company Inc, $14,233.00

RICHARD GREENBERG
049 - Safety, Tolerability of Two 2X40 mg Regimens of Recombivax, (463106), Merck and Company Inc, $565.00

RICHARD GREENBERG
99-BMT-106: Safety and Efficacy of Oral Levofloxacin vs. Parenteral Ceftriazone and Amikacin with the Potential of Conversion to Oral Ciprofloxacin and Amoxicillin/Clavulanate in the Treatm, (463243), Advanced Biologics, ($4,300.00)

RICHARD GREENBERG
A randomized, double-blind, multi-center, comparative phase I study of Intravenous BMS-284756 followed by oral BMS 284756 versus intravenous ceflaxone..., (464580), Bristol Myers Squibb Company, $2.00

RICHARD GREENBERG
Phase III, 1:1 randomized, double-blind, controlled, multicenter trial comparing the efficacy and safety of abacavir versus zidovudine when combined with Lami-vudine and efavirenz for treatment of HIV-1 infection in antiretroviral therapy naive adults, (464682), Glaxo Wellcome, $2.00

RICHARD GREENBERG
Protocol 008-01 Study to Evaluate the Safety, Tolerability & Immunogenicity of the HIV-1 Gag DNA Vaccine Formulated with PBS or with Aluminum Phosphage Followed by AD5 HIV-1 Gag Vaccine in a Prime Boost Regimen, (464883), Merck and Company Inc, $2.00

RICHARD GREENBERG
Protocol RP59500V-396 Synercid in the Treatment of Infection Caused by Vacomycin-Resistant Enterococcus Faecium (VREF), (464884), Aventis Pharmaceuticals Products Inc, $2.00

RICHARD GREENBERG
GS-99-903 Phase 3 Tenofovir DF in ART Naive Patients, (464091), Gilead Sciences Inc, $7,345.00

RICHARD GREENBERG
Vaccine Trial, (463927), Univ of Maryland at Baltimore, $150,322.00

RICHARD GREENBERG
00-BMT-123: A Phase III, Randomized, Paralled, Placebo-Controlled, Double-Blind, Multicenter Efficacy and Safety Study of Ramoplanin and Placebo in Neutropenic Oncology Patients., (464220), PharmaNet Inc, $17,850.00

RICHARD GREENBERG
AG 1549-508, (464154), Agouron Pharmaceuticals, $8,500.00

RICHARD GREENBERG
Synsorb Cd, Phase III, Clinical Trial for the Treatment of Clostridium Difficile-Associated Disease, (464174), Synsorb Biotech Inc, $3,780.00

RICHARD GREENBERG/CLAIRE POMEROY
A Phase 2/3 48wk, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily vs. Lamivudine 150mg BID in Combination with Zidovudine 300mg BID and Efavirenz 600mg Once Daily...., (463558), Glaxo Wellcome, $11,133.00

RICHARD GREENBERG/CLAIRE POMEROY
An Open-Label, Extension Study of Emtricitabine (Coviracil/FTC) in Patients Who are a Virologic Success and Currently Enrolled in FTC-303, (463568), Triangle Pharmaceuticals, $4,087.00

RICHARD GREENBERG/CLAIRE POMEROY
A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg bid), Efavirenz (600mg qd)/Didanosine (400mg qd-Hydroxyurea (600mg bid) in HIV-1 Infected...., (463647), Glaxo Wellcome, ($2,350.00)

RICHARD GREENBERG/GEORGE DAVIS
A Phase IV, Non-Comparative Study to Evaluate FORTOVASE TID in Combination With Two NRTIs in HIV-1 Infected Women and Men, (462881), Roche Laboratories, $940.00

RITA MUNN
Angiogenesis in Breast Carcinoma -- The Role of Vascular Endothelial Growth Factor, (429534), Ephraim McDowell Cancer Research Fdtn, ($18,088.00)

RITA MUNN
* A Randomized, Double-Blind, Multicenter Study of Low- Dose Gallium Nitrate for Treatment of Bone Metastases Due to Breast Cancer, (429626), SoloPak Pharmaceutical Inc, $3,000.00

ROLANDO BERGER
A Prospective, Multicenter Study of the Anemia of Critical Illness & Transfusion in the Critically Ill Patient, (464442), Ortho Biotech Inc, $8,725.00

SANTOSH MENON
RP 54563-313-The Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and of Tirofiban Versus Placebo in the Treatment of Acute Myocardial Infarction for Patients Not Thromblysed: , (463816), Rhone Poulenc, $3,748.00

SHIRISH BARVE/DONALD COHEN/CRAIG MCCLAIN
EtOH a Cofactor in AIDS: Modulation of TH1 and TH2 Cells, (429435), Natl Institute on Alcohol Abuse and Alcoholism, ($22,874.00)

SHIRISH BARVE/RICHARD GREENBERG
Alcohol Abuse, C-D4+ Depletion and HIV Pathogenesis, (464398), Natl Institute on Alcohol Abuse and Alcoholism, $18,829.00

SLAWOMIR KUSMIREK
Octave, (464760), PPD Development, $2,140.00

STEPHEN BROWN
Prophylaxis of aGVHD by inhibiting IR-induced NFkB, (464322), Univ of South Carolina, $40,145.00

STEPHEN SZILVASSY
Engraftment Studies of Expanded Hematopoietic Stem Cells, (462752), Natl Heart Lung and Blood Institute, $542,362.00

STEVEN HAIST
Pre-Doctoral Training in Primary Care, (464012), Health Professions Bureau, $237,600.00

STEVEN POST/ALAN DAUGHERTY
* Scavenger Receptor and G Protein Function in Macrophages, (464262), Natl Heart Lung and Blood Institute, $206,229.00

STEVEN SHEDLOFSKY
A Relative Bioavailability Study of Ribavirin Administerred Orally as Tablet Versus Capsule Forms to Patients with Chronic Hepatitis C (CHC) Infection, (464391), Hoffmann La Roche Inc, $14,717.00

STEVEN SHEDLOFSKY/ROBERT BLOUIN/RICHARD GREENBERG/DANIELL HILL/CRAIG MCCLAIN
Alcohol-Induced Cytochromes P450 and HCV Oxidative Injury, (464281), Natl Institute on Alcohol Abuse and Alcoholism, $253,400.00

THOMAS KELLY/ROBERT FREDERICH JR/ANGELA MAKRIS/CRAIG RUSH
* The Effects of Modafinil on Food Intake in Humans, (464211), Natl Institute on Drug Abuse, $27,000.00

THOMAS WAID
Double-Blind, randomized, parallel group study on gastrointestinal tolerability of ERL080A vs. mycophenolate mofetil (Cellcept) in renal transplant patients., (464582), Novartis, $2,889.00

THOMAS WAID/JOHN THOMPSON
Prograf (tacrolimus) as Secondary Intervention VS Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure, (462842), Fujisawa Pharmaceuticals, $78,700.00

THOMAS WHAYNE JR
Community Based Lipid Lowering Program in a Rural Appalachian Region, (463183), Warner Lambert Company, $100,000.00

THOMAS WHAYNE JR
Role of Lipid-lowering Agents on the Control of Blood Pressure Druing Angiotensin II Antagonism, (464058), Wake Forest Univ, $2.00

VAL ADAMS/GEORGE DAVIS/PHILIP DESIMONE/MICHAEL DOUKAS/DANIEL WERMELING
* Protocol EFG 10002 A Double Blind, Placebo Controlled Parallel Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral GW572016 Doses in Healthy Subjects, (464802), Glaxo Wellcome, $2.00

VAL ADAMS/JAMES BRYSON
* N-substituted Benzamides in Graft Versus Host Disease, (462617), Oxigene Inc, ($61,245.00)

WILLEM DE VILLIERS
A Phase III, Multi-National, Multi-Site, Double-Blind, Placebo-Controlled, 28 Week Study to Assess the Safety & Efficacy of the Engineered Human Anti-TNFa Antibody, CDP571 (10mg/kg), in Patient With Active Crohn's Disease, (464797), Celltech Chiroscience Ltd, $2.00

WILLEM DE VILLIERS
A Phase III, multi-national, multi-site, double-blind, placebo-controlled, 28 week study to assess the safety and efficacy of the engineered human anti-TNF anti-body, CDP571 (10mg/kg), in patients with active Crohn's disease, (464798), Celltech Chiroscience Ltd, $2.00

WILLEM DE VILLIERS
A Multi-Center, Placebo-Controlled Evaluation of the Safety & Efficacy of Two Dosage Levels of OP2000 (75 mg and 125 mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis, (464479), Incara Pharmaceuticals, $4,345.00

WILLEM DE VILLIERS/GARY VARILEK
A Phase II, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-arm, Dose Comparason Study of the Efficacy and Safety of the Oral Formulation of OPC-6535 Tablets, (464059), Otsuka America Pharmaceutical Inc, $2.00

WILLEM DE VILLIERS/GARY VARILEK
A Randomized Double-Blind, Placebo-Controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-Term Treatment of Patients with Moderately to Severely Active Crohn's Disease, (462716), Centocor Inc, $40,000.00

WILLEM DE VILLIERS/GARY VARILEK
A Randomized, Double Masked, Placebo Controlled Study of Subcutaneously Administered Recombinant Human Interleukin 11 (rhIL-11) in Patients with Active Crohn's Disease Not Treated with Prednisone, (463184), Genetics Institute, $2,500.00

WILLEM DE VILLIERS/GARY VARILEK
A Randomized, Double-Blind, Placebo Controlled Trial of Anti-TNF CChimeric Monoclonal Antibody (Infliximab. Remicade) in the Long-Term Treatment of Patients with Fistulizing Crohn's Disease (BB-IND 5389), (463654), Centocor Inc, $14,098.00

WILLEM DE VILLIERS/ION DEACIUC
CD36 and Hepatic Stellate Cell Activation, (464050), Natl Institute on Alcohol Abuse and Alcoholism, $141,850.00

WILLIAM ABRAHAM
InSync clinical Trial for Multisite Stimulation, (464077), Medtronics Inc, $59,900.00

WILLIAM ABRAHAM
Technology Assessment of Chronicle Implantable Hemodynamic Monitor, (464104), Medtronics Inc, $92,000.00

WILLIAM ABRAHAM
Oral Enoximone in Intravenous Inotrope-Dependent Subjects (EMOTE), (464386), Clinical Cardiovascular Research, $2.00

WILLIAM ABRAHAM
Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), (464235), Duke Univ Medical Center, $4,243.00

WILLIAM ABRAHAM
Prospective Evaluation and Indentification of Cardiac Decompensation in Patients with Heart Failure by Impedance Cardiography (PREDICT), (464298), CardioDynamics, $5,770.00

WILLIAM ABRAHAM
A Randomized, Open-Label Preference Study of Gengraf Compared to Neoral in Stable Solid-Organ Transplant Subjects: Protocol M99-33, (464155), Abbott Laboratories, $2.00

WILLIAM ABRAHAM
InSync ICD: Clinical Study Evaluating Cardiac Resynchronization Therapy for Heart Failure Patients with ICD Indications, (464231), Medtronics Inc, $15,200.00

WILLIAM ABRAHAM
InSync III: Clinical Study to Evaluate the Safety & Effectiveness of the Model 8042 & Attain OTW Lead Model 4193 in Heart Failure Patients, (464480), Medtronics Inc, $155,850.00

WILLIAM ABRAHAM
Nurse Support for Medtronic Trials, (464808), Medtronics Inc, $2.00

WILLIAM ABRAHAM
Double-Blind, Randomized, Parallel, Pharmacokinetic and Safety Study of Ranolazine SR 750 mg., (464617), CV Therapeutics, $2.00

WILLIAM ABRAHAM
A Double-Blind, Randomized Trial of Intravenous Primacor as Initiating Therapy for Oral Beta-Blocker Introduction in Patients Hospitalized with New York Heart Association Function Class III/IV Heart Failure, (464618), Sanofi Synthelabo Inc, $2.00

WILLIAM ABRAHAM/SANTOSH MENON
Candesartan Cilexetil in Heart Failure: Reduction in Mortality and Morbidity (CHARM); Study of Cadesartan in Patients with Heart Failure and Preserved Left Ventricular Systolic Function (SH-AHS-0007); Protocol.., (463216), Astra Pharmaceutical Co, $24,450.00

WILLIAM ABRAHAM/SANTOSH MENON
Multinational, Multicenter, Double-Blind, Randomized, Active Controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-Term Treatment with Valsartan, Captopril and their Combination on Mortality in High Risk Patients after, (462583), Duke Univ Medical Center, $2,600.00

WILLIAM MARKESBERY/MARK LOVELL
* Brain Oxidation in the Pathogenesis of Alzheimers Disease: Project 4A, (433578), Natl Institute on Aging, $145,521.00


* Cross-referenced accounts where the project director/s are affiliated with more than one department, college or center
Information Systems
Questions:
 Deborah Davis,  Office of Sponsored Projects Administration, 112 Kinkead Hall, 0057, 257-8311

UK Awards Home    Research    University of Kentucky